Estimating Cardiovascular Risk in Spain by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice.

[1]  A. Goday,et al.  Estimación del riesgo cardiovascular en España según la guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica , 2015 .

[2]  C. Brotons,et al.  Impacto de la utilización de las diferentes tablas SCORE en el cálculo del riesgo cardiovascular , 2014 .

[3]  A. Goday,et al.  Consumo de fármacos relacionados con el tratamiento de la diabetes mellitus y otros factores de riesgo cardiovascular en la población española. Estudio Di@bet.es , 2013 .

[4]  J. González.  Contribuciones de la mortalidad cardiovascular a la esperanza de vida de la población española de 1980 a 2009 , 2013 .

[5]  F. Soriguer,et al.  Mediterranean Diet Adherence in Individuals with Prediabetes and Unknown Diabetes: The Di@bet.es Study , 2013, Annals of Nutrition and Metabolism.

[6]  V. Fuster,et al.  Risk factor control for coronary artery disease secondary prevention in large randomized trials. , 2013, Journal of the American College of Cardiology.

[7]  Shah Ebrahim,et al.  [European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)]. , 2013, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[8]  F. Rodríguez‐Artalejo,et al.  Cardiovascular Health in a Southern Mediterranean European Country: A Nationwide Population-Based Study , 2013, Circulation. Cardiovascular quality and outcomes.

[9]  F. Tinahones,et al.  Metabolic syndrome and vascular risk estimation in a Mediterranean non-diabetic population without cardiovascular disease. , 2012, European journal of internal medicine.

[10]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[11]  E. Barrett-Connor,et al.  Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. , 2011, Circulation.

[12]  Duncan J Macfarlane,et al.  Validity of the international physical activity questionnaire short form (IPAQ-SF): A systematic review , 2011, The international journal of behavioral nutrition and physical activity.

[13]  R. Gomis,et al.  Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study , 2011, Diabetologia.

[14]  D. Betteridge,et al.  Lipid control in patients with diabetes mellitus , 2011, Nature Reviews Cardiology.

[15]  M. Grau,et al.  Validez relativa de la estimación del riesgo cardiovascular a 10 años en una cohorte poblacional del estudio REGICOR , 2011 .

[16]  E. Negri,et al.  Coronary heart disease and cerebrovascular disease mortality in young adults: recent trends in Europe , 2011, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[17]  Eliseo Guallar,et al.  Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study , 2011, European heart journal.

[18]  Rowena J Dolor,et al.  Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. , 2011, Journal of the American College of Cardiology.

[19]  Zahi A Fayad,et al.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Circulation.

[20]  M. Budoff,et al.  2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary , 2010 .

[21]  The Emerging Risk Factors Collaboration.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.

[22]  M. Grau,et al.  La función calibrada REGICOR mejora la clasificación de los pacientes de alto riesgo tratados con estatinas respecto a Framingham y SCORE en la población española , 2009 .

[23]  R. Califf,et al.  Sex differences in mortality following acute coronary syndromes. , 2009, JAMA.

[24]  Ian Graham,et al.  How much does HDL cholesterol add to risk estimation? A report from the SCORE investigators , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[25]  D. Orozco-Beltrán,et al.  Valoración del riesgo cardiovascular en la fase transversal del estudio Mediterránea , 2009 .

[26]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[27]  O. Pedersen,et al.  Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.

[28]  Douglas G Altman,et al.  [The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies]. , 2007, Gaceta sanitaria.

[29]  D. Orozco-Beltrán,et al.  Concordancia de las escalas REGICOR y SCORE para la identificación del riesgo cardiovascular alto en la población española , 2007 .

[30]  S. Pocock,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, PLoS medicine.

[31]  S. Galea,et al.  Participation rates in epidemiologic studies. , 2007, Annals of epidemiology.

[32]  Lourdes Cañón-Barroso,et al.  Comparación de las tablas REGICOR y SCORE para la clasificación del riesgo cardiovascular y la identificación de pacientes candidatos a tratamiento hipolipemiante o antihipertensivo , 2007 .

[33]  E. Rodilla,et al.  Comparación entre el algoritmo de Framingham y el de SCORE en el càlculo del riesgo cardiovascular en sujetos de 40-65 años , 2006 .

[34]  J. García,et al.  Comparación de los modelos SCORE y REGICOR para el cálculo del riesgo cardiovascular en sujetos sin enfermedad cardiovascular atendidos en un centro de salud de Barcelona , 2005 .

[35]  C. Lahoz,et al.  La aplicación de las tablas del SCORE a varones de edad avanzada triplica el número de sujetos clasificados de alto riesgo en comparación con la función de Framingham , 2005 .

[36]  J. García,et al.  Epidemiología de las enfermedades cardiovasculares y factores de riesgo en atención primaria , 2005 .

[37]  J. Manson,et al.  A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women , 2005, The New England journal of medicine.

[38]  C. Brotons,et al.  Adaptación española de la Guía Europea de Prevención Cardiovascular. , 2004 .

[39]  Shah Ebrahim,et al.  JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .

[40]  J. Marrugat,et al.  Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada , 2003 .

[41]  Jixian Wang,et al.  Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies , 2002, BMJ : British Medical Journal.

[42]  J. Marrugat,et al.  High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. REGICOR Investigators. , 1998, Journal of epidemiology and community health.

[43]  Wenyaw Chan,et al.  Statistical Methods in Medical Research , 2013, Model. Assist. Stat. Appl..

[44]  A. Sposito,et al.  Most of the patients presenting myocardial infarction would not be eligible for intensive lipid-lowering based on clinical algorithms or plasma C-reactive protein. , 2011, Atherosclerosis.

[45]  Fabio Salamanca-Gómez,et al.  Roberto Martínez Martínez , 2011 .

[46]  G. Moneta.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2011 .

[47]  J. B. Díez.  La función calibrada REGICOR mejora la clasificación de los pacientes de alto riesgo tratados con estatinas respecto a Framingham y SCORE en la población española , 2009 .

[48]  S. Allender,et al.  European cardiovascular disease statistics , 2008 .

[49]  G. Moneta.  A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women , 2007 .

[50]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice , 2004 .